- DOI:
-
https://doi.org/10.57187/5519
Clinical reasoning: Case report
Vol. 156 No. 11 (2026)
Expanding the clinical and geographical spectrum of PARK-LRRK2 p.(Asn1437His): first report in a Swiss family
-
Cite this as:
-
Swiss Med Wkly. 2026;156:5519
-
Published
-
16.11.2026
Summary
INTRODUCTION: Pathogenic variants in the LRRK2 gene represent the most common monogenic cause of Parkinson’s disease. Individual variants differ in frequency, geographical distribution and genotype-phenotype associations. Here, we report a Swiss family with multiple affected individuals carrying a very rare ROC-domain variant and provide a comprehensive characterisation of their clinical phenotype.
CLINICAL FINDINGS: Age at onset was earlier than typically reported for PARK-LRRK2. Leg tremor was frequently the initial presenting symptom, followed by the development of an asymmetric akinetic-rigid syndrome with a clear dopaminergic response. Constipation was commonly reported, whereas significant cognitive symptoms were not evident. Notably, despite the high penetrance of the variant, disease progression was relatively mild.
PRIMARY DIAGNOSIS: Genetic testing identified a heterozygous missense variant in the LRRK2 gene (c.4309A>C, p.(Asn1437His)), classified as likely pathogenic according to ACMG criteria.
CONCLUSION: The present work expands both the geographical distribution of this rare ROC-domain variant and suggests that it may be associated with earlier onset but not necessarily greater disease severity. Continued characterisation of rare LRRK2 variants is essential for refining genotype-phenotype correlations and supporting emerging targeted therapies.
References
- 1. Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt EJ, Laabs BH, et al. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study. Brain. 2024 Aug 1;147(8):2652-2667. doi:10.1093/brain/awae188
- 2. Taymans JM, Fell M, Greenamyre T, Hirst WD, Mamais A, Padmanabhan S, et al. Perspective on the current state of the LRRK2 field. npj Parkinson's Disease. 2023 Jul 1;9(1):104. doi:10.1038/s41531-023-00544-7
- 3. Krüger C, Lim SY, Buhrmann A, Fahrig FL, Gabbert C, Bahr N, et al. Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson´s disease. npj Parkinson's Disease. 2025 Feb 17;11(1):30. doi:10.1038/s41531-025-00881-9
- 4. Simpson C, Vinikoor-Imler L, Nassan FL, Shirvan J, Lally C, Dam T, et al. Prevalence of ten LRRK2 variants in Parkinson's disease: A comprehensive review. Parkinsonism & Related Disorders. 2022 May;98:103-113. doi:10.1016/j.parkreldis.2022.05.012
- 5. Segers K, Benoit F, Levy S, Martinet V, Schulz JG, Bertrand F, et al. G2019S Mutation of Leucine-Rich Repeat Kinase 2 Is a Cause of Lewy Body Dementia in Patients With North African Ancestors. Alzheimer Disease & Associated Disorders. 2024 Oct;38(4):328-331. doi:10.1097/WAD.0000000000000643
- 6. Correia Guedes L, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, Sampaio C. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A systematic review. Parkinsonism & Related Disorders. 2010 May;16(4):237-242. doi:10.1016/j.parkreldis.2009.11.004
- 7. Alessi DR, Sammler E. LRRK2 kinase in Parkinson's disease. Science. 2018 Apr 6;360(6384):36-37. doi:10.1126/science.aar5683
- 8. Kalogeropulou AF, Purlyte E, Tonelli F, Lange SM, Wightman M, Prescott AR, et al. Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding. Biochemical Journal. 2022 Sep 16;479(17):1759-1783. doi:10.1042/BCJ20220161
- 9. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine. 2015 May;17(5):405-424. doi:10.1038/gim.2015.30
- 10. Aasly JO, Vilariño‐Güell C, Dachsel JC, Webber PJ, West AB, Haugarvoll K, et al. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Movement Disorders. 2010 Oct 15;25(13):2156-2163. doi:10.1002/mds.23265
- 11. Puschmann A, Englund E, Ross OA, Vilariño-Güell C, Lincoln SJ, Kachergus JM, et al. First neuropathological description of a patient with Parkinson’s disease and LRRK2 p.N1437H mutation. Parkinsonism & Related Disorders. 2012 May;18(4):332-338. doi:10.1016/j.parkreldis.2011.11.019
- 12. Turski P, Chaberska I, Szukało P, Pyska P, Milanowski Ł, Szlufik S, et al. Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson’s disease. Frontiers in Neuroscience. 2022 Sep 20;16:971270. doi:10.3389/fnins.2022.971270
- 13. Puschmann A, Jiménez-Ferrer I, Lundblad-Andersson E, Mårtensson E, Hansson O, Odin P, et al. Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. Parkinsonism & Related Disorders. 2019 Sep;66:158-165. doi:10.1016/j.parkreldis.2019.07.032
- 14. Marras C, Schuele B, Munhoz RP, Rogaeva E, Langston JW, Kasten M, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology. 2011 Jul 26;77(4):325-333. doi:10.1212/wnl.0b013e318227042d Available from: www.neurology.org
- 15. Healy DG, Falchi M, O'sullivan SS, Bonifati V, Durr A, Bressman S. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. 2008;583. doi:10.1016/S1474
- 16. Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohé CF, et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. European Journal of Human Genetics. 2006 Mar;14(3):322-331. doi:10.1038/sj.ejhg.5201539
- 17. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain. 2005 Dec 1;128(12):2786-2796. doi:10.1093/brain/awh667
- 18. Jennings D, Huntwork‐Rodriguez S, Vissers MFJM, Daryani VM, Diaz D, Goo MS, et al. LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease. Movement Disorders. 2023 Mar;38(3):386-398. doi:10.1002/mds.29297